Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emerenziana Marturano

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Haematology|March 14, 2012
Primary CNS lymphomaAndrés J M Ferreri, Emerenziana Marturano
Leukemia Research|December 8, 2010
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilizationEnrico Orciuolo, Gabriele Buda, Emerenziana Marturano, et al.
Hematological Oncology|November 20, 2012
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapySilvia Mappa, Emerenziana Marturano, Giada Licata, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Haematology|March 14, 2012
Primary CNS lymphomaAndrés J M Ferreri, Emerenziana Marturano
Leukemia Research|December 8, 2010
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilizationEnrico Orciuolo, Gabriele Buda, Emerenziana Marturano, et al.
Hematological Oncology|November 20, 2012
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapySilvia Mappa, Emerenziana Marturano, Giada Licata, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Pageof 1